Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMOPHYLLIN-CRT vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline acts as a bronchodilator via nonselective phosphodiesterase inhibition, increasing intracellular c AMP levels. It also antagonizes adenosine receptors and may have anti-inflammatory effects.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Treatment of asthma and chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label),Facilitation of weaning from mechanical ventilation in neonates (off-label)
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
Theophylline 400 mg orally once daily (24-hour extended-release). Titrate based on serum theophylline levels; target trough 5-15 mcg/m L.
AEROLONE is not a recognized drug; no standard dosing available.
Terminal elimination half-life: 8-10 hours in adults (non-smokers); prolonged to 12-16 hours in elderly or hepatic impairment; reduced to 4-6 hours in smokers (CYP1A2 induction).
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism is saturable, leading to nonlinear pharmacokinetics. Less than 15% excreted unchanged in urine.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Primarily hepatic metabolism (90%) via CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for ~10% in adults, with minor biliary/fecal elimination (<1%).
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
~40% bound to albumin (primarily); binding is concentration-independent.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.4-0.6 L/kg (slightly higher in infants); approximates total body water; distributes widely into tissues including breast milk and CNS.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral immediate-release: 80-100%; Oral sustained-release: 90-100% (with less fluctuation); Rectal: 75-90% (variable due to absorption).
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
No specific dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce dose by 25% and monitor levels. For GFR <10 m L/min: reduce dose by 50% and monitor closely.
No data; not applicable.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and monitor levels. Child-Pugh Class C: reduce dose by 75% or consider alternative; monitor levels closely.
No data; not applicable.
Children >1 year: initial dose 10-16 mg/kg/day orally q12h (extended-release). Titrate to serum theophylline levels of 5-15 mcg/m L. Maximum 400 mg/day or 16 mg/kg/day, whichever is less.
No data; not applicable.
Elderly patients: start at lowest possible dose (e.g., 200-300 mg once daily) due to reduced clearance. Monitor serum theophylline levels closely; target lower end of therapeutic range (5-12 mcg/m L). Avoid use if possible due to increased risk of toxicity.
No data; not applicable.
Theophylline has a narrow therapeutic index; toxicity can occur at doses only slightly above therapeutic levels. Serious and potentially fatal adverse events, including seizures and cardiac arrhythmias, can occur, especially in patients with preexisting conditions or those receiving concurrent medications that affect theophylline clearance.
None
Monitor serum theophylline concentrations closely due to narrow therapeutic index (10-20 mcg/m L).,Use with caution in patients with cardiac disorders (e.g., arrhythmias), hepatic impairment, renal dysfunction, seizure disorders, and in elderly patients.,May exacerbate gastric ulcers and gastroesophageal reflux.,Drug interactions: CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones, macrolides) increase levels; CYP1A2 inducers (e.g., smoking, rifampin, phenytoin) decrease levels.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or any component of the formulation,Pre-existing seizure disorders (relative),Active peptic ulcer disease (relative),Uncontrolled cardiac arrhythmias (relative)
Hypersensitivity to arformoterol or any component of the formulation
Avoid charcoal-broiled foods as they may decrease theophylline levels. High-fat meals can alter absorption; take consistently with regard to meals. Caffeine-containing foods and beverages should be limited due to additive stimulation.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Theophylline (active ingredient in SOMOPHYLLIN-CRT) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxicity at high doses but no major malformations. Second and third trimesters: No established teratogenicity; may cause neonatal toxicity (irritability, jitteriness, vomiting) if maternal levels are high near term. Use only if benefit outweighs risk.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Breastfeeding is generally considered compatible but may cause irritability or sleep disturbances in the infant. Monitor infant for signs of theophylline toxicity. Use lowest effective maternal dose.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
During pregnancy, theophylline clearance may increase (especially in second and third trimesters), requiring dose adjustments. Monitor serum concentrations closely and increase dose as needed to maintain therapeutic levels. Clearance returns to non-pregnant levels postpartum.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
SOMOPHYLLIN-CRT (theophylline) is a controlled-release formulation for chronic asthma/COPD. Monitor serum theophylline levels (target 5-15 mcg/m L). Avoid in active seizures. Use with caution in hepatic impairment, heart failure, and elderly. Cimetidine, fluoroquinolones, and macrolides increase levels; smoking and phenytoin decrease levels.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Swallow tablets whole; do not crush or chew.,Take at the same time each day with a full glass of water.,Avoid excessive caffeine (coffee, tea, cola, chocolate) to prevent increased stimulation.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Do not change brand or formulation without consulting your doctor.,Store at room temperature, away from moisture.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMOPHYLLIN-CRT vs AEROLONE, answered by our medical review team.
SOMOPHYLLIN-CRT is a Bronchodilator that works by Theophylline acts as a bronchodilator via nonselective phosphodiesterase inhibition, increasing intracellular c AMP levels. It also antagonizes adenosine receptors and may have anti-inflammatory effects.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMOPHYLLIN-CRT and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMOPHYLLIN-CRT is: Theophylline 400 mg orally once daily (24-hour extended-release). Titrate based on serum theophylline levels; target trough 5-15 mcg/m L.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMOPHYLLIN-CRT and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMOPHYLLIN-CRT is classified as Category C. Theophylline (active ingredient in SOMOPHYLLIN-CRT) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxicity at high doses. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.